Mizuho lifts target to USD 100.00 for Dexcom stock

Published on 10/17/2026 at 20:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dexcom schedules third-quarter results for October 29, 2026. Dexcom stock was last at USD 86.04 on October 16, 2026, down 1.90 percent on Nasdaq.

Targets and dates

Mizuho analyst Anthony Petrone raised the Dexcom target to USD 100.00 from USD 95.00 on October 13, 2026.
Dexcom plans to publish third-quarter 2026 results on October 29, 2026.
Dexcom stock was last at USD 86.04 on October 16, 2026 at 4:00 p.m. ET, down 1.90 percent on Nasdaq.
Dexcom had a USD 32.5 billion market capitalization and a P/E ratio of 34.01 on October 16, 2026.

Architektur-Render moderner Glas-Campus, goldene Stunde, Palmen, kein Schild — Dexcom Inc. Architektur-Render des modernen Unternehmens-Campus in San Diego ISIN US2521311074 Medizintechnik, Illustration mit AI erstellt.

Mizuho analyst Anthony Petrone raised the price target for DexCom, Inc. to USD 100.00 from USD 95.00 on October 13, 2026, while keeping an Outperform rating, as Markets Insider reported. The new target stands 16.23 percent above the USD 86.04 last price.

Dexcom stock was last at USD 86.04 on October 16, 2026 at 4:00 p.m. ET, down 1.90 percent on Nasdaq versus the USD 87.71 prior close. The price was 7.07 percent below the USD 92.59 52-week high and 59.02 percent above the USD 54.11 low.

Second-quarter revenue reached USD 1.31 billion

For the second quarter of 2026, revenue came to USD 1.31 billion, consolidated net income reached USD 249.1 million and diluted earnings per share were USD 0.64. Operating margin was 24.00 percent for the quarter. These figures put revenue 9.78 percent above the USD 1.19 billion reported for the first quarter of 2026.

October 29 results set the next date

Dexcom plans to release its third-quarter 2026 results after the market closes on October 29, 2026, with a conference call at 4:30 p.m. ET, according to the company's investor release dated October 7, 2026, published on Dexcom. For the second quarter, operating cash flow was USD 269.2 million.

Comparison with peers

Dexcom Inc. (Nasdaq, USD): minus 1.90 percent, P/E 34.01, market capitalization USD 32.5 billion.
Tandem Diabetes Care (Nasdaq, USD): minus 1.69 percent, P/E minus 17.49, market capitalization USD 1.1 billion.
Insulet (Nasdaq, USD): plus 1.68 percent, P/E 26.37, market capitalization USD 9.8 billion.

Valuation and trading position

Dexcom carried a market capitalization of USD 32.5 billion and a P/E ratio of 34.01 on October 16, 2026. Trading volume was 3,500,493 shares against an average volume of 4,350,178 shares, placing the session volume 19.53 percent below its average.

Dexcom Inc. last traded at USD 86.04 on October 16, 2026 at 4:00 p.m. ET on Nasdaq. The next scheduled results date is October 29, 2026.